Pharmabiz4h
Santhera reports positive results from LIONHEART study with Agamree demonstrating unique mineralocorticoid receptor antagonism
Santhera reports positive results from LIONHEART study with Agamree demonstrating unique mineralocorticoid receptor antagonism: Pratteln, Switzerland Thursday, October 3, 2024, 18 ...
Pharmabiz5h
NRx Pharma announces 12-month real-time stability on first manufactured commercial scale lot of NRX-100
NRx Pharma announces 12-month real-time stability on first manufactured commercial scale lot of NRX-100: Radnor, Pennsylvania Thursday, October 3, 2024, 17:00 Hrs [IST] NRx Pharma ...
Pharmabiz6h
Dr Reddy’s inks voluntary licensing pact with Gilead to manufacture and commercialise lenacapavir in India and other countries
Dr Reddy’s inks voluntary licensing pact with Gilead to manufacture and commercialise lenacapavir in India and other countries: Our Bureau, Bengaluru Thursday, October 3, 2024, ...
Pharmabiz6h
KIMS inks MoU with Intuitive to launch 25 new robotic surgery programmes; Expanding accessibility in tier 2 & 3 cities
KIMS inks MoU with Intuitive to launch 25 new robotic surgery programmes; Expanding accessibility in tier 2 & 3 cities ...
Pharmabiz7h
CDSCO becomes affiliated member of IMDRF
The Central Drugs Standard Control Organization (CDSCO) has received approval from International Medical Device Regulators Forum (IMDRF) as an affiliate member of the Forum. The ministry of health and ...
Pharmabiz7h
Sapience Therapeutics begins patient enrolment in phase 2 study of first-in-class ß-catenin antagonist, ST316 in colorectal cancer
Tarrytown, New York Thursday, October 3, 2024, 15:00 Hrs [IST] ...
Pharmabiz8h
Qiagen introduces QIAcuityDx digital PCR system for clinical testing in oncology
Qiagen introduces QIAcuityDx digital PCR system for clinical testing in oncology: Venlo, the Netherlands Thursday, October 3, 2024, 14:00 Hrs [IST] Qiagen N.V., a Netherlands-base ...
Pharmabiz10h
FIP publishes reference document on access to safe and quality essential medicines
FIP publishes reference document on access to safe and quality essential medicines: Our Bureau, Bengaluru Thursday, October 3, 2024, 12:45 Hrs [IST] International Pharmaceutical F ...
Pharmabiz10h
Biocon Biologics refinances US$ 1.1 billion long term debt through US$ bonds and new syndicated facility
Biocon Biologics refinances US$ 1.1 billion long term debt through US$ bonds and new syndicated facility: Our Bureau, Bengaluru Thursday, October 3, 2024, 12:30 Hrs [IST] Biocon B ...
Pharmabiz10h
Gilead's licensing agreement for lenacapavir a move to preserve its monopoly, alleges TWN
Gilead's licensing agreement for lenacapavir a move to preserve its monopoly, alleges TWN: Our Bureau, New Delhi Thursday, October 3, 2024, 12:20 Hrs [IST] Third World Network (TW ...
Pharmabiz10h
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 12:10 Hrs [IST] The Joint United Nations Progra ...
Pharmabiz10h
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403: Cambridge, Massachusetts Thursday, October 3, 2024, 12:00 Hrs [IST] Moderna, Inc, a global l ...